EP Edge™ The Signal

Niraj Sharma MD FACC FHRS: Cardiac Electrophysiologist
  • 5.0 (1)
  • LIFE SCIENCES

Monthly clinical deep analysis in cardiac electrophysiology: AF, VT, SVT, ablation, devices, antiarrhythmic drugs, and high-impact trials. The Signal: physician-level analysis that identifies what matters in EP and translates evidence into clinical practice. EP Edge™: The Signal is the flagship monthly podcast from EP Edge, delivering structured, expert-level interpretation for electrophysiologists, cardiologists, fellows, and clinically engaged practitioners. Each episode goes beyond summaries to integrate evidence across trials, guidelines, mechanisms, and real-world practice. Episodes cover the full spectrum of electrophysiology, including atrial and ventricular arrhythmias, supraventricular tachycardias, antiarrhythmic pharmacology, pacing and defibrillator strategies, mapping and ablation technologies (including pulsed field ablation), and emerging data shaping clinical decision-making. This is not a news recap—it is a curated synthesis focused on what truly changes practice. Content combines mechanistic insight, cross-trial evidence review, critical appraisal of methodology and outcomes, and practical application in the EP lab and clinic. EP Edge™: The Signal complements the weekly EP Edge™: Journal Watch by providing deeper analysis and clinical synthesis. For patient-focused education, explore EP Edge™: Heart Talk. Available as both podcast and newsletter via EP Edge on LinkedIn and Substack: https://epedge.substack.com/

Episodes

  1. EP Edge Newsletter Part III: Pulsed Field Ablation Complications — Hemolysis, Coronary Spasm, Silent Stroke, Phrenic Nerve Injury, and CIED Interaction

    FEB 25

    EP Edge Newsletter Part III: Pulsed Field Ablation Complications — Hemolysis, Coronary Spasm, Silent Stroke, Phrenic Nerve Injury, and CIED Interaction

    Pulsed field ablation (PFA) has rapidly transformed atrial fibrillation ablation, offering a non-thermal mechanism of myocardial injury through irreversible electroporation. While early clinical trials emphasized its favorable safety profile compared with radiofrequency and cryoablation, expanding real-world experience has revealed a distinct complication spectrum driven by high-voltage electric field interactions with myocardium, coronary arteries, blood, nerves, and cardiac implantable electronic devices. Unlike thermal injury, these complications are mediated by electrical, autonomic, and vascular effects, including delayed coronary vasospasm, malignant ventricular arrhythmias, and transient electrical instability. Understanding these mechanisms is critical as pulsed field ablation becomes more widely adopted in electrophysiology practice. This episode explores key complications including intravascular hemolysis and associated acute kidney injury, coronary artery spasm and ischemia, silent cerebral ischemic lesions, phrenic nerve injury, esophageal temperature elevation, and neuromuscular stimulation such as laryngospasm. These risks are strongly influenced by catheter design, lesion burden, waveform characteristics, and proximity to vulnerable structures. We also examine the interaction between pulsed field ablation and pacemakers and implantable cardioverter-defibrillators (ICDs), including transient pacing inhibition, electromagnetic interference, and rare cases of permanent device malfunction. As pulsed field ablation expands into more complex lesion sets and broader patient populations, recognizing these platform-specific risks is essential for procedural planning, patient selection, and post-procedural monitoring. Full references, detailed analysis, graphs, and visual summaries are available on the EP Edge Newsletter on LinkedIn, and the complete long-form article is also available on Substack at epedge.substack.com. If you have any questions, suggestions, or feedback, please contact epedgecast@gmail.com.

    30 min
  2. EP Edge Newsletter Part II: Pulsed Field Ablation Trials — ADVENT, PULSED AF, Sphere-9, VARIPULSE, VOLT, INSIGHT, and PULSAR

    FEB 18

    EP Edge Newsletter Part II: Pulsed Field Ablation Trials — ADVENT, PULSED AF, Sphere-9, VARIPULSE, VOLT, INSIGHT, and PULSAR

    In this episode of the EP Edge Newsletter Podcast, we analyze the pivotal clinical trials that established pulsed field ablation (PFA) as a major technological advancement in atrial fibrillation ablation. We examine the foundational FDA-approval studies, including the PULSED AF trial evaluating the Medtronic PulseSelect system and the ADVENT randomized trial comparing FARAPULSE pulsed field ablation with conventional radiofrequency and cryoballoon ablation. These trials demonstrated that pulsed field ablation achieves high rates of acute pulmonary vein isolation with freedom from atrial arrhythmia recurrence comparable to thermal ablation, while maintaining a favorable safety profile and procedural efficiency. Importantly, these studies defined modern clinical endpoints for catheter ablation success, including composite measures incorporating arrhythmia recurrence, antiarrhythmic drug use, cardioversion, and repeat ablation.  PFA Part II We also explore next-generation pulsed field ablation platforms, including the Sphere-9 lattice-tip catheter, VARIPULSE system, and VOLT balloon-in-basket catheter, each designed to improve lesion durability, catheter stability, and procedural reproducibility. These studies demonstrate consistently high rates of pulmonary vein isolation, favorable safety outcomes, and evolving workflow advantages, including reduced fluoroscopy use and efficient lesion delivery. We then examine the latest randomized and investigational trials, including INSIGHT, which compared nanosecond pulsed field ablation with optimized ablation-index guided radiofrequency ablation, and the PULSAR IDE trial evaluating spherical array catheter design for durable pulmonary vein isolation. These trials highlight a critical reality in atrial fibrillation ablation: long-term success is determined not only by energy source, but by catheter design, tissue contact, lesion geometry, and pulmonary vein isolation durability.  PFA Part II Full references, detailed discussion, figures, and graphical summaries are available on the EP Edge Newsletter on LinkedIn, as well as the complete long-form article on Substack at epedge.substack.com. If you have questions, suggestions, or feedback, please contact epedgecast@gmail.com.

    42 min
  3. EP Edge Newsletter Part I: Pulsed Field Ablation (PFA) — Electroporation, Biophysics, Engineering, Tissue Selectivity, and Lesion Formation

    FEB 11

    EP Edge Newsletter Part I: Pulsed Field Ablation (PFA) — Electroporation, Biophysics, Engineering, Tissue Selectivity, and Lesion Formation

    In this foundational episode of the EP Edge Newsletter Podcast, we examine the scientific and engineering principles underlying pulsed field ablation (PFA), a transformative advance in catheter ablation for atrial fibrillation. Unlike radiofrequency or cryoablation, which rely on thermal injury, pulsed field ablation produces myocardial lesions through irreversible electroporation, a non-thermal mechanism that disrupts the cell membrane by applying precisely controlled electric fields. This represents a fundamental shift in ablation biology, where lesion formation is governed not by heat, but by transmembrane voltage thresholds, membrane destabilization, and controlled cellular injury. This episode traces the history of electroporation, from its origins in physics and industrial biotechnology to its adoption in oncology as a non-thermal tumor ablation modality and eventual translation into cardiac electrophysiology. We then explore the Engineering Trinity of pulsed field ablation—the waveform, catheter, and pulse generator—and how these components interact to determine lesion size, safety profile, tissue selectivity, and procedural effectiveness. Understanding this integrated engineering system is essential to interpreting differences between pulsed field ablation platforms and explains why voltage alone does not define lesion durability or procedural success. We also examine the cellular and molecular mechanisms of PFA lesion formation, including nanopore creation within the lipid bilayer, calcium influx, ATP depletion, mitochondrial dysfunction, and regulated cell death pathways. These membrane-driven injury mechanisms produce lesions that differ fundamentally from thermal ablation, preserving extracellular architecture while eliminating cardiomyocytes. This unique biology underlies one of the most important advantages of pulsed field ablation—tissue selectivity, where myocardial cells demonstrate greater susceptibility to irreversible electroporation compared with surrounding structures such as the esophagus, nerves, and vasculature, enabling effective ablation with reduced collateral injury risk. Finally, we review the histopathology and structural evolution of pulsed field ablation lesions, including sharply demarcated injury zones, preserved tissue scaffolding, and progressive fibrocellular remodeling over time. These distinctive lesion characteristics explain both the safety profile and long-term behavior of pulsed field ablation and provide critical insight into how electrophysiologists should interpret acute procedural endpoints and long-term durability. Full references, detailed discussion, figures, and visual summaries are available on the EP Edge Newsletter on LinkedIn, as well as the full long-form edition on Substack at epedge.substack.com. If you have questions, suggestions, or feedback, please email epedgecast@gmail.com

    20 min
  4. Cannabis and the Heart: Atrial Fibrillation, Arrhythmias, Stroke, Myocardial Infarction and Sudden Cardiac Risk Explained

    12/22/2025

    Cannabis and the Heart: Atrial Fibrillation, Arrhythmias, Stroke, Myocardial Infarction and Sudden Cardiac Risk Explained

    In this EP-EDGE podcast episode, Dr. Niraj Sharma, cardiac electrophysiologist, breaks down the latest evidence linking modern high-THC cannabis to cardiovascular and electrophysiologic risk. Drawing from large real-world datasets, mechanistic studies, and global meta-analyses, this episode explains how today’s cannabis products—vapes, edibles, dabs, and synthetic cannabinoids—are very different from the low-potency marijuana of the past. We explore the science behind CB1 receptor activation, autonomic imbalance, endothelial dysfunction, platelet activation, and how these mechanisms translate into real-world clinical outcomes—including: Atrial fibrillation and supraventricular tachycardiaPremature atrial and ventricular beatsVentricular tachycardia and ventricular fibrillationMyocardial infarction and stroke in young adultsEndothelial dysfunction as an early vascular warning signWhy high-potency THC and route of use (vaping, edibles, dabs) matterThis episode reviews landmark studies from JACC Advances, Heart, JAMA Cardiology, European Heart Journal, and Heart Rhythm, including massive EHR-based cohorts involving millions of patients. We also address common misconceptions, including why some older studies show neutral risk—and why those findings do not apply to modern high-potency cannabis use. Whether you are a cardiologist, electrophysiologist, primary care clinician, or an informed patient, this episode provides a clear, evidence-based framework to understand why modern cannabis is not cardiovascularly benign and how it should be discussed in clinical practice—especially in patients with atrial fibrillation, ventricular arrhythmias, or unexplained cardiac events. References, infographics, and detailed study breakdowns are available in the EP-EDGE LinkedIn Newsletter (December 2025 issue).

    24 min
  5. When Atrial Fibrillation Ablation Fails: Have We Reached the Limit or Just the Wrong Target?

    11/23/2025

    When Atrial Fibrillation Ablation Fails: Have We Reached the Limit or Just the Wrong Target?

    In this issue, we trace the fascinating evolution of atrial fibrillation (AF) therapy — from the Cox Maze procedure to Haïssaguerre’s discovery of pulmonary vein ectopy, through Pappone’s wide antral isolation, and onward to the era of pulse field ablation (PFA). We explore how ablation technologies have transformed — radiofrequency, cryo, and PFA — yet the success rates remain stubbornly static. Why do some ablations fail? Are we reaching the limits of substrate modification, or simply targeting the wrong mechanisms? Join Dr. Sharma as he dissects the mechanistic layers of ablation failure — from pulmonary vein reconnection and atrial substrate remodeling to inflammation, fibrosis, and autonomic imbalance. The discussion looks ahead to next-generation strategies that may redefine success in AF therapy. If you enjoy this episode, subscribe and share the podcast to help grow the EPH community. For questions, suggestions, or collaboration ideas, reach out at EPEdgeCast@gmail.com

    12 min
  6. Targeting the Intrinsic Pathway: Is Factor XI Inhibition Poised to Redefine Stroke Prevention in AF: EP Edge August 2025 Issue 4A

    10/28/2025

    Targeting the Intrinsic Pathway: Is Factor XI Inhibition Poised to Redefine Stroke Prevention in AF: EP Edge August 2025 Issue 4A

    What if stroke prevention in atrial fibrillation no longer meant trading protection for bleeding risk? Factor XI inhibition—led by trials like AZALEA–TIMI 71, LILAC–TIMI 76, and LIBREXIA–AF—is poised to rewrite the anticoagulation playbook. By targeting the intrinsic pathway, these agents may decouple thromboembolic protection from major bleeding, potentially reshaping the role of left atrial appendage occlusion (LAAO) in stroke prevention strategies. In this episode of EP Edge, Dr. Niraj Sharma breaks down the evolving data, drug classes, mechanistic rationale, and implications for future guidelines—while also looking at where structural interventions may still fit in this shifting landscape. For: Source data/infographics see EPEDGE Newsletter on LinkedIn For feedback, collaborations, or questions, email Dr. Niraj Sharma at epedgecast@gmail.com or connect on LinkedIn

    10 min
  7. First-Line VT Ablation: Trials, Tools & Timing: EP Edge Newsletter June 2025

    10/28/2025

    First-Line VT Ablation: Trials, Tools & Timing: EP Edge Newsletter June 2025

    The paradigm is shifting. Ventricular tachycardia (VT) ablation is stepping out of the shadows—from rescue therapy to first-line strategy, driven by landmark trials like VANISH2, PAUSE-SCD, and PARTITA. Meanwhile, pulse field ablation (PFA) continues its rapid evolution—crossing over from atrial to ventricular applications—but questions about durability and embolic safety persist. In this episode of EP Edge, Dr. Niraj Sharma takes you through the key data shaping modern electrophysiology, from trial outcomes to emerging technology, including injectable light-activated pacemakers and telomere-targeting strategies that may redefine longevity and prevention. Whether you’re an EP, a general cardiologist, or in allied research, this episode offers evidence-based insights and forward-looking perspectives on where rhythm science is heading.For: Source data/infographics see EPEDGE Newsletter on LinkedInFor feedback, collaborations, or questions, email Dr. Niraj Sharma at epedgecast@gmail.com or connect on LinkedIn

    8 min
  8. Left Atrial Appendage Occlusion (LAAO): Where We Stand in 2025: EP Edge Newsletter 4B August 2025

    10/28/2025

    Left Atrial Appendage Occlusion (LAAO): Where We Stand in 2025: EP Edge Newsletter 4B August 2025

    Left atrial appendage occlusion (LAAO) has evolved from a niche option for oral anticoagulation–intolerant patients to a frontline procedural strategy for stroke prevention in atrial fibrillation. Landmark trials like OPTION, SWISS‑APERO, and COMBINATION are redefining how and when we use these devices. In this episode of EP Edge, Dr. Niraj Sharma walks through the historical arc of LAAO, key evidence shaping contemporary practice, procedural complications often under-recognized (like silent cerebral lesions), and where the field is headed with AI, new device designs, and competition from Factor XI inhibitors. This is essential listening for electrophysiologists, interventional cardiologists, and rhythm specialists navigating the next era of stroke prevention. For: Source data/infographics see EPEDGE Newsletter on LinkedInFor feedback, collaborations, or questions, email Dr. Niraj Sharma at epedgecast@gmail.com or connect on LinkedIn

    9 min
  9. Pulse Field Ablation: Promise, Peril, and the AI Revolution in EP: EP Edge Newsletter May 2025

    10/28/2025

    Pulse Field Ablation: Promise, Peril, and the AI Revolution in EP: EP Edge Newsletter May 2025

    Pulse field ablation (PFA) has been hailed as the next frontier in atrial fibrillation therapy—nonthermal, ultra-selective, and lightning fast. But as new data emerges, important questions are rising about its systemic effects, cerebral safety, and vascular complications. In this episode of EP Edge, Dr. Niraj Sharma unpacks the latest findings from the NEMESIS-PFA registry, explores silent cerebral lesion data, reviews a rare case of catastrophic coronary spasm, and introduces how AI—through models like DeePRISM—is changing how we think about ablation strategy. Whether you’re in the lab, in clinic, or leading research, this episode offers a critical look at where the field is heading next.For: Source data/infographics see EPEDGE Newsletter on LinkedInFor feedback, collaborations, or questions, email Dr. Niraj Sharma at epedgecast@gmail.com or connect on LinkedIn

    9 min
  10. Lifestyle Modification and Atrial Fibrillation: Redefining the role of the Electrophysiologist: EP Edge Newsletter July 2025

    10/28/2025

    Lifestyle Modification and Atrial Fibrillation: Redefining the role of the Electrophysiologist: EP Edge Newsletter July 2025

    Ablation is powerful—but lifestyle is transformative. As atrial fibrillation (AF) continues to rise globally, emerging evidence makes it clear: lifestyle modification is not just complementary care, it’s frontline therapy. In this episode of EP Edge, Dr. Niraj Sharma explores how structured lifestyle interventions—targeting weight, alcohol use, sleep apnea, blood pressure, diabetes, and physical activity—can rival or even surpass the outcomes of ablation alone. We’ll discuss key data from landmark trials, gender differences in response, and how the modern electrophysiologist’s role is evolving—beyond the lab and into lifestyle medicine.For: Source data/infographics see EPEDGE Newsletter on LinkedIn For feedback, collaborations, or questions, email Dr. Niraj Sharma at epedgecast@gmail.com or connect on LinkedIn

    15 min
  11. Beyond CRT: LBBAP and the New Era of Physiological Pacing — Promise and Pitfalls: EP Edge Newsletter October 2025 Issue 5

    10/27/2025

    Beyond CRT: LBBAP and the New Era of Physiological Pacing — Promise and Pitfalls: EP Edge Newsletter October 2025 Issue 5

    In this episode of EP Edge Podcast, Dr. Niraj Sharma dives deep into the clinical promise and procedural realities of LBBAP: Clinical advantages: improved LVEF, narrower QRS, lower VT/VF and AF incidence.RV protection: reduced risk of pacing-induced cardiomyopathy.Sex-specific outcomes: women with NICM + LBBB derive greater benefit.Complications: lead fracture, TR progression, microperforations, and capture failure.Future directions: integrating imaging, refining technique, and advancing lead technology This is where physiology meets precision—and where CRT is being redefined. For: Source data/infographics see EPEDGE Newsletter on LinkedInFor feedback, collaborations, or questions, email Dr. Niraj Sharma at epedgecast@gmail.com or connect on LinkedIn

    11 min
  • 11 Episodes

About

Monthly clinical deep analysis in cardiac electrophysiology: AF, VT, SVT, ablation, devices, antiarrhythmic drugs, and high-impact trials. The Signal: physician-level analysis that identifies what matters in EP and translates evidence into clinical practice. EP Edge™: The Signal is the flagship monthly podcast from EP Edge, delivering structured, expert-level interpretation for electrophysiologists, cardiologists, fellows, and clinically engaged practitioners. Each episode goes beyond summaries to integrate evidence across trials, guidelines, mechanisms, and real-world practice. Episodes cover the full spectrum of electrophysiology, including atrial and ventricular arrhythmias, supraventricular tachycardias, antiarrhythmic pharmacology, pacing and defibrillator strategies, mapping and ablation technologies (including pulsed field ablation), and emerging data shaping clinical decision-making. This is not a news recap—it is a curated synthesis focused on what truly changes practice. Content combines mechanistic insight, cross-trial evidence review, critical appraisal of methodology and outcomes, and practical application in the EP lab and clinic. EP Edge™: The Signal complements the weekly EP Edge™: Journal Watch by providing deeper analysis and clinical synthesis. For patient-focused education, explore EP Edge™: Heart Talk. Available as both podcast and newsletter via EP Edge on LinkedIn and Substack: https://epedge.substack.com/

Information

  • Creator
    Niraj Sharma MD FACC FHRS: Cardiac Electrophysiologist
  • Years Active
    2025 - 2026
  • Episodes
    11
  • Rating
    Clean
  • Copyright
    © 2026 Niraj Sharma MD FACC FHRS: Cardiac Electrophysiologist

You Might Also Like